These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 26010678)

  • 21. The EPIC study: a lesson to learn.
    Auerswald G; Kurnik K; Aledort LM; Chehadeh H; Loew-Baselli A; Steinitz K; Reininger AJ;
    Haemophilia; 2015 Sep; 21(5):622-8. PubMed ID: 25912619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A.
    Zhang L; Zhao Y; Sun J; Wang X; Yu M; Yang R
    Haemophilia; 2011 Mar; 17(2):191-5. PubMed ID: 20860578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient Data Meta-analysis of rAFH-PFM Post-Authorization Safety Studies.
    Romanov V; Marcucci M; Cheng J; Thabane L; Iorio A
    Thromb Haemost; 2015 Jul; 114(1):56-64. PubMed ID: 26017627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion.
    Fernandez M; Yu T; Bjornson E; Luu H; Spotts G
    Blood Coagul Fibrinolysis; 2006 Apr; 17(3):165-71. PubMed ID: 16575253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study.
    Pollmann H; Klamroth R; Vidovic N; Kriukov AY; Epstein J; Abraham I; Spotts G; Oldenburg J
    Ann Hematol; 2013 May; 92(5):689-98. PubMed ID: 23324986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor VIII--Baxter: rAHF-PFM, recombinant anti-haemophilic factor--protein-free method, recombinant factor VIII--protein-free.
    Drugs R D; 2003; 4(6):366-8. PubMed ID: 14584967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Octocog alfa, plasma/albumin-free method.
    McCormack PL; Plosker GL
    Drugs; 2005; 65(18):2613-20, discussion 21-2. PubMed ID: 16392876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
    Fischer K; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Iorio A; Gilman E; Makris M;
    Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
    Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
    Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability of lyophilized and reconstituted plasma/albumin-free recombinant human factor VIII (ADVATE rAHF-PFM).
    Parti R; Schoppmann A; Lee H; Yang L
    Haemophilia; 2005 Sep; 11(5):492-6. PubMed ID: 16128893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group.
    Seremetis S; Lusher JM; Abildgaard CF; Kasper CK; Allred R; Hurst D
    Haemophilia; 1999 Jan; 5(1):9-16. PubMed ID: 10215942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
    Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
    Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
    Bray GL; Gomperts ED; Courter S; Gruppo R; Gordon EM; Manco-Johnson M; Shapiro A; Scheibel E; White G; Lee M
    Blood; 1994 May; 83(9):2428-35. PubMed ID: 8167332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
    Kim SK; Yoo KY; Lee KS; Hwang T; Choi YM; Choi EJ; Park SK
    J Korean Med Sci; 2018 Jan; 33(1):e5. PubMed ID: 29215814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
    Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
    Rusen L; Kavakli K; Korth-Bradley J; Huard F; Rendo P; Fuiman J; Baumann JA; Smith L; Alvey C; Rupon J
    Haemophilia; 2018 Jul; 24(4):604-610. PubMed ID: 29582525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.